D. E. Shaw & Co. Inc. Has $5.82 Million Stock Holdings in Encompass Health Co. (NYSE:EHC)

D. E. Shaw & Co. Inc. raised its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 335.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 62,994 shares of the company's stock after buying an additional 48,517 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.06% of Encompass Health worth $5,817,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. MassMutual Private Wealth & Trust FSB raised its stake in Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after acquiring an additional 137 shares during the last quarter. Colonial Trust Co SC purchased a new position in shares of Encompass Health in the fourth quarter worth about $29,000. Transce3nd LLC acquired a new stake in shares of Encompass Health during the fourth quarter worth about $40,000. CBIZ Investment Advisory Services LLC increased its stake in shares of Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after acquiring an additional 127 shares during the period. Finally, Tompkins Financial Corp purchased a new stake in shares of Encompass Health in the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 97.25% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on EHC shares. William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. Truist Financial reaffirmed a "buy" rating and set a $135.00 price objective (up previously from $116.00) on shares of Encompass Health in a report on Monday, April 28th. UBS Group raised their price objective on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research note on Monday, April 28th. StockNews.com raised Encompass Health from a "hold" rating to a "buy" rating in a research report on Sunday, May 11th. Finally, KeyCorp increased their target price on shares of Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $120.86.

Insider Buying and Selling

In other news, insider Elissa Joy Charbonneau sold 4,279 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total transaction of $498,974.19. Following the sale, the insider now owns 11,958 shares in the company, valued at $1,394,422.38. The trade was a 26.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Mark J. Tarr sold 118,384 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total value of $14,387,207.52. Following the transaction, the chief executive officer now directly owns 527,070 shares in the company, valued at $64,054,817.10. The trade was a 18.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 132,663 shares of company stock worth $16,034,082 in the last ninety days. 2.00% of the stock is currently owned by corporate insiders.

Encompass Health Stock Performance

NYSE:EHC traded up $0.49 during midday trading on Tuesday, reaching $121.67. 751,820 shares of the company traded hands, compared to its average volume of 694,326. The firm has a market capitalization of $12.26 billion, a price-to-earnings ratio of 27.28, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. The company has a fifty day moving average price of $105.97 and a 200 day moving average price of $100.90. Encompass Health Co. has a twelve month low of $82.74 and a twelve month high of $121.98. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04.

Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the business earned $1.12 EPS. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts expect that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's dividend payout ratio is presently 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.